[Public Notice+] Daehan New Pharm Reports Q1 Operating Profit of 5.6 Billion KRW, Up 16% YoY

[Asia Economy Reporter Hyunseok Yoo] Daehan New Pharm announced on the 12th through a public disclosure that it achieved an operating profit of 5.6 billion KRW in the first quarter, marking a 16% increase compared to the same period last year. Sales increased by 13% to 35.5 billion KRW, and net profit also rose by 14% to 3.6 billion KRW.

The company explained that the growth in sales was driven by the expansion of its animal pharmaceutical division. Additionally, steady overseas exports have continuously expanded its presence in both domestic and international markets. A Daehan New Pharm official stated, “Our company is focusing on diversifying sales channels and research and development to expand our pharmaceutical and animal pharmaceutical businesses,” adding, “We will accelerate performance growth by continuously launching well-being medicines such as vitamin injections and specialized pharmaceuticals.”

Meanwhile, Daehan New Pharm is also expanding its rapidly growing pet-related business. In February, it launched ‘Pipnil Spot-on,’ an external antiparasitic dewormer for pets containing the active ingredient fipronil, which was approved as an animal drug in Korea. According to data from the Korea Rural Economic Institute, the pet-related market size is expected to reach 6 trillion KRW by 2027.

This content was produced with the assistance of AI translation services.